Related Experiment Video

Updated: Mar 8, 2026

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.7K

Synthetic lethality: emerging targets and opportunities in melanoma

Nicola Thompson1, David J Adams1, Marco Ranzani1

  • 1Experimental Cancer Genetics, The Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire, UK.

Pigment Cell & Melanoma Research
|January 19, 2017
PubMed

Insights

Synthetic lethality offers a novel strategy for melanoma treatment by targeting cancer cells with specific mutations. This approach exploits genetic vulnerabilities to kill tumor cells, paving the way for new drug discovery.

Area of Science:

  • Oncology
  • Cancer Genetics
  • Pharmacology

Background:

  • Melanoma treatment has advanced with targeted therapies and immunotherapy.
  • Synthetic lethality remains an underexplored therapeutic strategy for melanoma.
  • This approach leverages cancer-specific genetic alterations for selective tumor cell killing.

Purpose of the Study:

  • To explore the potential of synthetic lethality in melanoma treatment.
  • To outline methods for identifying synthetic lethal interactions.
  • To define the role of synthetic lethality in driving drug discovery.

Main Methods:

  • Review of existing literature on synthetic lethality.
  • Analysis of genetic vulnerabilities in melanoma.
  • Discussion of strategies for identifying synthetic lethal partners.

Main Results:

  • Synthetic lethality exploits somatically acquired changes, particularly driver mutations.
  • Identification of potential synthetic lethal interactions in melanoma.
  • Framework for translating synthetic lethal interactions into therapeutic strategies.

Conclusions:

  • Synthetic lethality presents a promising avenue for novel melanoma therapies.
  • Further research is needed to fully harness synthetic lethality for drug development.
  • This strategy has the potential to overcome resistance to current treatments.
Keywords:
CRISPRmelanoma genomicspreclinical modelssynthetic lethalitytherapeutic target

More Related Videos

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

1.3K
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

3.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.0K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
60